Canada Invests C$23.8 Million to Expand Radiopharmaceutical Manufacturing for Advanced Medical Treatments

Canada is investing C$23.8 million in a major expansion of Jubilant Radiopharma’s manufacturing facility in Kirkland, Quebec, as the country works to strengthen its domestic capacity to produce medicines used in advanced medical imaging and targeted treatments. Announced on October 8, 2026, the federal contribution will support a C$94.5 million project designed to modernize production infrastructure, expand research capabilities and reinforce Canada’s role in the radiopharmaceutical supply chain.

The investment comes as radiopharmaceuticals become increasingly important in modern medicine, particularly in the diagnosis and treatment of cancer and cardiovascular conditions. These specialized medicines contain radioactive isotopes that can help doctors identify disease or deliver radiation to targeted tissues.

For Canada, expanding manufacturing capacity is about more than industrial growth. It also concerns the reliable production of time-sensitive medical products that hospitals and nuclear medicine departments depend on.

A C$94.5 Million Project to Expand Canadian Production

The Government of Canada announced that its Strategic Response Fund would contribute C$23.8 million toward Jubilant Radiopharma’s facility modernization and expansion in Kirkland, Quebec. The company’s overall project is valued at C$94.5 million.

The planned work includes modernizing production lines, establishing additional production space and upgrading laboratory, storage and shipping areas used for radiopharmaceutical products. The facility is intended to develop into a global centre of excellence for radiopharmaceutical production and research and development.

The project is also expected to create and maintain 225 high-quality jobs in Quebec and provide 35 co-operative placements for students. The company plans to strengthen collaborations with Canadian universities, research institutions and small and medium-sized businesses, including work connected to artificial intelligence-assisted diagnostics and nuclear medicine research.

The investment is part of a wider effort to expand Canada’s ability to manufacture critical biomedical products domestically. The federal government said that, since 2020, it has invested more than C$2.5 billion across 43 projects in the biomanufacturing, vaccine and therapeutics ecosystem.

The latest announcement, however, is specifically focused on Jubilant Radiopharma’s Quebec facility rather than a nationwide funding programme dedicated exclusively to radiopharmaceutical manufacturers.

What Makes Radiopharmaceuticals Different?

Radiopharmaceuticals are medicines that contain radioactive substances, known as radionuclides, combined with compounds designed to interact with particular tissues, organs or biological targets.

Their applications generally fall into two broad categories: diagnosis and treatment.

Diagnostic radiopharmaceuticals can help physicians observe biological processes inside the body. After administration, the radioactive component emits signals that specialized imaging equipment can detect. Techniques such as positron emission tomography, or PET, use these signals to produce images that help clinicians investigate disease.

Therapeutic radiopharmaceuticals use radiation to damage or destroy targeted cells. Certain treatments are designed to deliver radiation to cancer cells while limiting exposure to surrounding healthy tissue, although the degree of targeting and the risk of side effects depend on the medicine and its clinical use.

These products are not interchangeable with conventional medicines. Their radioactive components can have short half-lives, meaning their activity decreases over time. Some diagnostic products must therefore be manufactured, quality-tested and delivered within tightly controlled time windows.

Production also requires specialized equipment, radiation-safety procedures and rigorous quality controls. Expanding manufacturing facilities can consequently involve much more than adding ordinary pharmaceutical production lines.

Why Domestic Manufacturing Capacity Matters

A dependable supply of radiopharmaceuticals depends on a coordinated chain of activities, from producing medical isotopes to preparing the final medicine and delivering it to a healthcare facility.

Disruptions at any stage can complicate access to diagnostic scans or treatments. This is particularly important for products with limited usable lifetimes, for which conventional stockpiling may not be practical.

Canada already has capabilities in medical isotope production, supported by nuclear reactors, particle accelerators and specialized research infrastructure. Nevertheless, the production of an isotope and the manufacture of a finished radiopharmaceutical are different stages of the supply chain.

The isotope must be incorporated into an appropriate compound, processed under suitable conditions, tested for quality and safety, and prepared for its intended medical application. Expanding a dedicated manufacturing facility can strengthen this downstream capacity.

The Kirkland project is intended to increase Jubilant Radiopharma’s production capabilities and improve the infrastructure supporting its laboratory and logistics operations. These upgrades could help the company respond to demand for radiopharmaceutical products, although the government announcement does not establish a specific national supply increase or guarantee that shortages will be eliminated.

The project also supports a broader objective: maintaining domestic expertise in products that combine pharmaceutical manufacturing, nuclear science and specialized medical applications.

The Role of Radiopharmaceuticals in Cancer Care and Medical Imaging

Radiopharmaceuticals have become important tools in several areas of clinical medicine.

In diagnostic imaging, radioactive tracers can reveal information about the function of tissues and organs that may not be apparent from anatomy alone. Depending on the tracer and imaging method, clinicians can investigate cancer, cardiovascular disease and other medical conditions.

In cancer treatment, selected radioactive compounds can deliver radiation to particular biological targets. Lutetium-177, for example, is used in certain targeted radionuclide therapies for conditions including some neuroendocrine tumours and prostate cancer.

These applications require different products, manufacturing processes and clinical evidence. A facility expansion does not itself establish that a new treatment has been developed, approved or made available to patients.

Instead, stronger manufacturing infrastructure can support the production and distribution of products that have already met the applicable regulatory requirements, as well as research and development aimed at future applications.

The federal government’s announcement describes the Kirkland expansion as a way to strengthen production and research capabilities. It does not identify a new radiopharmaceutical drug approval or a new clinical treatment resulting directly from the investment.

Manufacturing Quality Remains a Critical Challenge

Radiopharmaceutical manufacturing presents technical challenges that differ from those found in many conventional medicines.

Manufacturers must control chemical composition, radioactive purity, dose and other product characteristics. They also need to manage radiation exposure and comply with requirements governing pharmaceutical quality and nuclear safety.

For some diagnostic radiopharmaceuticals, radioactive decay creates particularly strict timing constraints. A product may have to move rapidly from production through testing and delivery so that it retains sufficient activity for its intended use.

Therapeutic products can have different requirements, including controls appropriate to their radioactive properties and the radiation doses they deliver. Manufacturing processes must be tailored to the specific product rather than treated as a single standard procedure for every radiopharmaceutical.

Facility modernization can provide improved production areas, laboratories and handling infrastructure, but the final quality and availability of medicines still depend on validated processes, regulatory compliance, reliable isotope supplies and effective distribution.

The Kirkland expansion is therefore an industrial-capacity investment, not a replacement for clinical evaluation or regulatory oversight.

Building on Canada’s Medical Isotope Infrastructure

Canada’s radiopharmaceutical ambitions extend beyond one company or facility. The country has also supported medical isotope production through initiatives involving nuclear energy infrastructure, research organizations and specialized technology developers.

For example, the federal government announced support in August 2025 for a further isotope-production system at Bruce Power’s nuclear facility in Ontario. The project was intended to increase production of lutetium-177, an isotope used in certain targeted cancer therapies.

That initiative focuses on isotope production, while the October 2026 investment supports the modernization and expansion of a facility that manufactures radiopharmaceutical products. The two developments address different parts of the wider nuclear medicine ecosystem.

Connecting reliable isotope production with specialized pharmaceutical manufacturing, quality testing and distribution is important to building a resilient supply chain.

The Kirkland project may strengthen one part of that system by expanding production infrastructure and supporting collaboration with Canadian research and education institutions. Its eventual contribution will depend on the facility’s implementation, the products manufactured there and the demand those products serve.

What Happens Next?

The announced C$94.5 million project will require facility upgrades, production-space expansion and improvements to supporting infrastructure. The federal announcement sets out the intended investment and employment outcomes but does not provide a confirmed completion date or quantify the resulting increase in output across all products.

Its longer-term significance will be measured by whether the upgraded facility can expand reliable production, support research and development, and contribute to a more resilient supply of radiopharmaceutical medicines.

For patients, the benefit is indirect rather than immediate: manufacturing investment can support access to important diagnostic and therapeutic products, but it does not by itself change treatment eligibility or guarantee faster access to care.

Canada’s investment illustrates a broader shift in life sciences policy toward strengthening domestic manufacturing capabilities for specialized medical products. As nuclear medicine advances, facilities that can reliably manufacture complex radiopharmaceuticals are likely to remain an important part of the healthcare supply chain.

Frequently Asked Questions

1. What did the Canadian government announce in October 2026?

On October 8, 2026, the Government of Canada announced C$23.8 million in Strategic Response Fund support for Jubilant Radiopharma’s C$94.5 million facility expansion and modernization project in Kirkland, Quebec.

2. What are radiopharmaceuticals used for?

Radiopharmaceuticals are used in medical imaging and in certain treatments. Diagnostic products help clinicians investigate diseases, while therapeutic products can deliver radiation to selected biological targets, including some cancer cells.

3. How will the Jubilant Radiopharma project expand manufacturing capacity?

The project will modernize production lines, create additional production space and upgrade laboratory, storage and shipping areas. It is also intended to strengthen research and development and collaborations with Canadian institutions.

4. Will the investment immediately improve access to cancer treatments?

Not necessarily. The project is intended to strengthen manufacturing capacity. Any effect on patient access will depend on implementation, production output, product availability, distribution and applicable regulatory requirements.

5. How is radiopharmaceutical manufacturing different from conventional drug production?

Radiopharmaceuticals contain radioactive materials that require specialized handling and quality controls. Some have short radioactive half-lives, making production, testing and delivery especially time-sensitive.